Drug intelligence / Profile preview

ausanil

Development stage
Discontinued
Lead developer
VR1 Corporation
Administration
Intranasal
01

Overview

Ausanil is a non-prescription, homeopathic nasal spray formulated to provide rapid pain relief for severe headaches—including tension, rebound, cluster headaches—and migraines. Its primary active ingredient is an extract from the oleoresin capsicum plant (chili pepper), specifically capsaicin. The mechanism of action involves local desensitization of the trigeminal nerve in the nasal mucosa and depletion of calcitonin gene-related peptide (CGRP), a key neurotransmitter involved in migraine pain signaling. This leads to reduced swelling and inflammation of blood vessels around the brain, resulting in fast-acting pain relief. Ausanil is not intended as a preventative or cure but as symptomatic treatment for acute headache episodes. It was developed by neurologist Dr. Anjan Chatterjee and commercialized by VR1 Corp., with its first launch in 2014[1][2][3][4][5]. Clinical studies have shown effectiveness rates comparable to prescription migraine medications but with minimal systemic side effects due to its localized intranasal delivery[2][3]. It is not recommended for mild or infrequent headaches, certain types of migraines (e.g., basilar), children under 18, pregnant or breastfeeding women, or those with specific nasal/respiratory conditions[2][4].

Brand names
Ausanil
Other names
capsicum annuum
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on ausanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ausanil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call